IMGN - ImmunoGen, Inc. Stock Price and Quote

IMGN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	0.30%	Shs Outstand	254.41M	Perf Week	-3.61%
Market Cap	915.30M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.00%	Shs Float	219.84M	Perf Month	-4.31%
Income	-222.90M	PEG	-	EPS next Q	-0.25	Inst Own	93.10%	Short Float / Ratio	10.37% / 6.43	Perf Quarter	-20.00%
Sales	108.80M	P/S	8.41	EPS this Y	-30.10%	Inst Trans	1.93%	Short Interest	22.80M	Perf Half Y	-23.66%
Book/sh	0.61	P/B	6.44	EPS next Y	2.10%	ROA	-55.30%	Target Price	12.33	Perf Year	-23.95%
Cash/sh	1.18	P/C	3.33	EPS next 5Y	-	ROE	-100.20%	52W Range	3.10 - 6.63	Perf YTD	-19.35%
Dividend	-	P/FCF	-	EPS past 5Y	2.10%	ROI	-142.60%	52W High	-39.67%	Beta	0.94
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	-1.20%	Gross Margin	99.80%	52W Low	29.24%	ATR	0.23
Employees	277	Current Ratio	2.50	Sales Q/Q	47.10%	Oper. Margin	-	RSI (14)	45.72	Volatility	4.45% 6.42%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-37.90%	Profit Margin	-	Rel Volume	0.48	Prev Close	3.93
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 01 BMO	Payout	-	Avg Volume	3.55M	Price	4.00
Recom	1.90	SMA20	-0.78%	SMA50	-7.53%	SMA200	-18.91%	Volume	487,986	Change	1.78%

Nov-21-22

Initiated

Truist

Buy

$10

Sep-09-22

Initiated

Barclays

Overweight

Mar-21-22

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$9 → $6

Feb-11-22

Initiated

BMO Capital Markets

Outperform

$18

Dec-01-21

Upgrade

Jefferies

Hold → Buy

$7 → $12

Oct-26-20

Resumed

H.C. Wainwright

Buy

$11

Oct-02-20

Upgrade

Guggenheim

Neutral → Buy

$14

Sep-29-20

Resumed

JP Morgan

Neutral

Dec-17-19

Reiterated

H.C. Wainwright

Buy

$5 → $9

Aug-13-19

Reiterated

H.C. Wainwright

Buy

$4 → $5

Show Previous Ratings

Mar-03-23 11:11AM	ImmunoGen, Inc. (NASDAQ:IMGN) Q4 2022 Earnings Call Transcript Insider Monkey
Mar-01-23 10:35PM	Q4 2022 ImmunoGen Inc Earnings Call Thomson Reuters StreetEvents
04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
01:27PM	ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing Benzinga
07:45AM	ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:30AM	Loading…
06:30AM	ImmunoGen Reports Recent Progress and 2022 Financial Results Business Wire
06:25AM	ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents Business Wire
Feb-22-23 04:30PM	ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire
10:00AM	Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-21-23 01:23AM	Heres Why ClearBridge Multi Cap Growth Strategy Exited ImmunoGen (IMGN) Insider Monkey -5.74%
Feb-16-23 05:34AM	With 72% institutional ownership, ImmunoGen, Inc. (NASDAQ:IMGN) is a favorite amongst the big guns Simply Wall St.
Feb-15-23 04:01PM	ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results Business Wire
Feb-01-23 04:30PM	ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire
Jan-04-23 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
06:30AM	ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs Business Wire
04:47AM	Loading…
04:47AM	Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock? Zacks
Jan-03-23 07:45AM	Need To Know: The Consensus Just Cut Its ImmunoGen, Inc. (NASDAQ:IMGN) Estimates For 2023 Simply Wall St.
Dec-30-22 09:30AM	Company News for Dec 30, 2022 Zacks
Dec-28-22 04:30PM	ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed Business Wire +7.47%
12:56PM	ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime Benzinga
Dec-27-22 04:30PM	ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference Business Wire
Dec-15-22 06:10AM	Will ImmunoGen (NASDAQ:IMGN) Spend Its Cash Wisely? Simply Wall St.
Dec-12-22 10:55AM	Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology Zacks
Dec-10-22 10:30AM	ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH Business Wire
Dec-09-22 06:30AM	ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia Business Wire
Dec-05-22 05:30AM	FDA Takes Tougher Line on Fast-Tracked Drugs The Wall Street Journal
Dec-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-21-22 06:30AM	ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer Business Wire
Nov-17-22 06:45AM	Industry Analysts Just Upgraded Their ImmunoGen, Inc. (NASDAQ:IMGN) Revenue Forecasts By 23% Simply Wall St.
05:52AM	The Petri Dish: Moderna touts new booster; MGH spins out diagnostics startup American City Business Journals
02:21PM	Loading…
Nov-16-22 02:21PM	After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst Benzinga
Nov-15-22 12:56PM	ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug Zacks -13.02%
06:16AM	FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer Benzinga
Nov-14-22 04:30PM	ImmunoGen Announces FDA Accelerated Approval of ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer Business Wire +7.46%
Nov-09-22 07:53AM	ImmunoGen Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags Simply Wall St. -6.14%
Nov-07-22 02:07PM	ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up Zacks
Nov-04-22 07:45AM	ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates Zacks
06:30AM	ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results Business Wire
Nov-03-22 08:48AM	Should You Buy ImmunoGen (IMGN) Ahead of Earnings? Zacks
Nov-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -5.39%
10:01AM	Marinus Pharmaceuticals (MRNS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
06:30AM	ImmunoGen Announces Departure of Chief Commercial Officer Business Wire
Oct-28-22 10:00AM	ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy? Zacks
08:40AM	ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO Business Wire
Oct-20-22 04:01PM	ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results Business Wire
Oct-03-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-29-22 08:00AM	ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS Business Wire
Sep-14-22 04:30PM	ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference Business Wire
Sep-11-22 06:00AM	ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO Business Wire
Sep-02-22 11:31AM	Why Is Pacira (PCRX) Down 9.2% Since Last Earnings Report? Zacks
Sep-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -5.16%
12:42PM	Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate Zacks
11:31AM	Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue? Zacks
Aug-31-22 06:30AM	ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm Business Wire
Aug-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
11:13AM	ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates Zacks
Jul-30-22 11:30AM	ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript Motley Fool
Jul-29-22 07:45AM	ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates Zacks -9.71%
06:30AM	ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results Business Wire
Jul-14-22 04:01PM	ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results Business Wire
Jul-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-14-22 10:02AM	ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline Zacks
Jun-13-22 01:28PM	We're Keeping An Eye On ImmunoGen's (NASDAQ:IMGN) Cash Burn Rate Simply Wall St. -7.08%
06:30AM	ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates Business Wire
Jun-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-26-22 05:00PM	ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO Business Wire +6.05%
May-25-22 04:30PM	ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire
May-24-22 09:39AM	ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review Zacks
May-23-22 07:59AM	ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy MarketWatch
06:30AM	ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review Business Wire
May-10-22 04:30PM	ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference Business Wire
May-06-22 01:30PM	ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript Motley Fool
07:45AM	ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:30AM	ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results Business Wire
May-03-22 08:55AM	10 Best Stocks to Buy Under $20 According to Jeremy Greens Redmile Group Insider Monkey
May-02-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.18%
Apr-28-22 11:18AM	Despite shrinking by US$77m in the past week, ImmunoGen (NASDAQ:IMGN) shareholders are still up 100% over 3 years Simply Wall St.
Apr-21-22 04:01PM	ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results Business Wire
Apr-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.30%
11:23AM	Is ImmunoGen Stock a Bargain After Dropping 39%? Motley Fool
Mar-31-22 04:30PM	ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference Business Wire
Mar-30-22 11:51AM	ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer Zacks
Mar-29-22 06:30AM	ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer Business Wire +11.72%
Mar-21-22 03:07PM	Why These 10 Stocks Are in the Spotlight on Monday Insider Monkey -18.25%
03:00PM	Why Coinbase and Immunogen Led the Nasdaq Lower Monday Motley Fool
08:26AM	Why Are ImmunoGen Shares Trading Lower Today Benzinga
Mar-19-22 07:15PM	ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting Business Wire
Mar-10-22 06:30AM	ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting Business Wire
Mar-01-22 04:30PM	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-28-22 10:20AM	ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates Zacks
Feb-27-22 09:16PM	Billionaire Ken Griffin Picks Up These 3 Strong Buy Stocks TipRanks
07:48AM	ImmunoGen, Inc. (NASDAQ:IMGN): Is Breakeven Near? Simply Wall St.
Feb-25-22 07:45AM	ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates Zacks +7.44%
06:30AM	ImmunoGen Reports Recent Progress and 2021 Financial Results Business Wire
Feb-23-22 04:30PM	ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference Business Wire
Feb-16-22 10:58AM	ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B Zacks
10:46AM	Biotech Stock Roundup: BDSI Surges on Merger Deal, SGEN Down on Outlook & More Zacks
Feb-15-22 11:19AM	Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B Benzinga
06:40AM	ImmunoGen shares jump 7% premarket on news of license deal with Lilly worth up to $1.7 billion MarketWatch
06:30AM	ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion Business Wire

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harrington-Smith Kristen	SVP & CHIEF COMMERCIAL OFFICER	Nov 15	Option Exercise	0.00	25,000	0	25,000	Nov 18 05:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience